New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...